CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer - PubMed (original) (raw)
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Bruno G Leclerc et al. Clin Cancer Res. 2016.
Abstract
Purpose: CD73 is an adenosine-generating ecto-enzyme that suppresses antitumor immunity in mouse models of cancer, including prostate cancer. Although high levels of CD73 are associated with poor prognosis in various types of cancer, the clinical impact of CD73 in prostate cancer remains unclear.
Experimental design: We evaluated the prognostic value of CD73 protein expression and CD8(+) cell density in 285 cases of prostate cancer on tissue microarray (TMA). Normal adjacent and tumor tissues were evaluated in duplicates.
Results: Univariate and multivariate analyses revealed that high levels of CD73 in normal adjacent prostate epithelium were significantly associated with shorter biochemical recurrence (BCR)-free survival. Notably, CD73 expression in normal epithelium conferred a negative prognostic value to prostate-infiltrating CD8(+) cells. Surprisingly, high levels of CD73 in the tumor stroma were associated with longer BCR-free survival in univariate analysis. In vitro studies revealed that adenosine signaling inhibited NF-κB activity in human prostate cancer cells via A2B adenosine receptors. Consistent with these results, CD73 expression in the prostate tumor stroma negatively correlated with p65 expression in the nuclei of prostate tumor cells.
Conclusions: Our study revealed that CD73 is an independent prognostic factor in prostate cancer. Our data support a model in which CD73 expression in the prostate epithelium suppresses immunosurveillance by CD8(+) T cells, whereas CD73 expression in the tumor stroma reduces NF-κB signaling in tumor cells via A2B adenosine receptor signaling. CD73 expression, including in normal adjacent prostate epithelium, can thus effectively discriminate between aggressive and indolent forms of prostate cancer.
©2015 American Association for Cancer Research.
Similar articles
- Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW, Li YC, Ma SR, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ. Deng WW, et al. Int J Cancer. 2018 Sep 15;143(6):1494-1504. doi: 10.1002/ijc.31534. Int J Cancer. 2018. PMID: 29663369 - CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou W, Wu W. Chen Q, et al. J Cell Mol Med. 2020 Aug;24(15):8674-8686. doi: 10.1111/jcmm.15500. Epub 2020 Jul 9. J Cell Mol Med. 2020. PMID: 32643277 Free PMC article. - Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B, Pommey S, Smyth MJ, Stagg J. Allard B, et al. Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983257 - Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B, Turcotte M, Stagg J. Allard B, et al. Expert Opin Ther Targets. 2014 Aug;18(8):863-81. doi: 10.1517/14728222.2014.915315. Epub 2014 May 6. Expert Opin Ther Targets. 2014. PMID: 24798880 Review. - Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
Yang J, Liao X, Yu J, Zhou P. Yang J, et al. Curr Med Chem. 2018;25(19):2260-2271. doi: 10.2174/0929867325666180117101114. Curr Med Chem. 2018. PMID: 29345574 Review.
Cited by
- The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.
Gardani CFF, Diz FM, Dondé LB, Rockenbach L, Laufer S, Morrone FB. Gardani CFF, et al. Front Immunol. 2024 Sep 17;15:1455469. doi: 10.3389/fimmu.2024.1455469. eCollection 2024. Front Immunol. 2024. PMID: 39355246 Free PMC article. Review. - Integrated multiomics revealed adenosine signaling predict immunotherapy response and regulate tumor ecosystem of melanoma.
Xu Y, Lau P, Chen X, Zhao S, He Y, Jiang Z, Chen X, Zhang G, Liu H. Xu Y, et al. Hum Genomics. 2024 Sep 15;18(1):101. doi: 10.1186/s40246-024-00651-3. Hum Genomics. 2024. PMID: 39278925 Free PMC article. - Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism.
Zhan J, Huang L, Niu L, Lu W, Sun C, Liu S, Ding Z, Li E. Zhan J, et al. Cell Commun Signal. 2024 Aug 1;22(1):387. doi: 10.1186/s12964-024-01755-y. Cell Commun Signal. 2024. PMID: 39090604 Free PMC article. Review. - GRHL2 suppression of NT5E/CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment.
Coban B, Wang Z, Liao CY, Beslmüller K, Timmermans MAM, Martens JWM, Hundscheid JHM, Slutter B, Zweemer AJM, Neubert E, Danen EHJ. Coban B, et al. iScience. 2024 Apr 12;27(5):109738. doi: 10.1016/j.isci.2024.109738. eCollection 2024 May 17. iScience. 2024. PMID: 38706844 Free PMC article. - A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS, Reeves J, Gandhi S, Spigel DR, Arrowsmith E, George DJ, Karlix J, Pouliot G, Hattersley MM, Gangl ET, James GD, Thompson J, Russell DL, Patel B, Kumar R, Lim E. Falchook GS, et al. Cancer Immunol Immunother. 2024 Mar 2;73(4):72. doi: 10.1007/s00262-024-03640-6. Cancer Immunol Immunother. 2024. PMID: 38430405 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials